![Recce Pharmaceuticals Ltd](/common/images/company/ASX_RCE.png)
Highlights: Phase I trial agreement with leading clinical research organization Human safety and tolerability study to assess infusion of RECCE® 327 in 40 healthy subjects as a single ascending...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.03 | 6.25 | 0.48 | 0.55 | 0.47 | 103546 | 0.50564434 | DE |
4 | -0.08 | -13.5593220339 | 0.59 | 0.62 | 0.4525 | 218142 | 0.48447143 | DE |
12 | 0.07 | 15.9090909091 | 0.44 | 0.695 | 0.415 | 180638 | 0.49867069 | DE |
26 | -0.075 | -12.8205128205 | 0.585 | 0.695 | 0.41 | 179121 | 0.4848628 | DE |
52 | -0.49 | -49 | 1 | 1.38 | 0.41 | 143089 | 0.66775176 | DE |
156 | 0.295 | 137.209302326 | 0.215 | 1.875 | 0.21 | 260623 | 0.75427992 | DE |
260 | 0 | 0 | 0 | 0.55 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.